Mizuho raised the firm’s price target on Haemonetics (HAE) to $75 from $65 and keeps an Outperform rating on the shares following the fiscal Q2 report. The post-earnings rally reflects stock the better than expected earnings on top of some short covering, the analyst tells investors in a research note. The firm sees an improved margin trajectory for Haemonetics.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics Reports Positive Earnings Call with Growth Highlights
- Haemonetics upgraded to Neutral from Underperform at BofA
- Haemonetics price target raised to $90 from $86 at Barrington
- Haemonetics price target raised to $82 from $65 at Baird
- Haemonetics Reports Improved Profitability Amid Revenue Decline